期刊文献+

近6年全球心血管药物研发现状分析 被引量:6

Analysis on research and development of global cardiovascular drugs in the past 6 years
在线阅读 下载PDF
导出
摘要 通过检索Integrity^(TM)数据库,获得2012年4月至2018年4月全球在研的12 906项心血管药物的数据进行统计分析,总结了近6年心血管药物研发的概貌、靶标、作用机制、专利信息、上市信息等多项指标,提示了心血管药物近年研发的特点,为相关新药研发人员提供理论参考。 Through the retrieval of Integrity TM,the data of12906cardiovascular drugs in the world from April2012to April2018were analyzed,and the general features of cardiovascular drugs research and development,target,mechanism,patent information and information on the market were summarized for the past6years,and the characteristics of cardiovascular drugs in recent years were suggested.This research may provide references for related R&D personnel.
作者 张静 ZHANG Jing(Library and Information Center,China Pharmaceutical University,Nanjing 211198,China)
出处 《中国药科大学学报》 CAS CSCD 北大核心 2018年第6期760-765,共6页 Journal of China Pharmaceutical University
基金 中央高校基本科研业务费校级平台基地资助项目(No.2016RPT003)~~
关键词 心血管药物 新药研发 靶标 INTEGRITY TM cardiovascular drugs drug development target Integrity TM
  • 相关文献

参考文献1

二级参考文献32

  • 1Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor [J]. Cardiovasc Drug Rev, 2002, 20: 303-328.
  • 2Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts [J]. Drug Discov Today, 2007, 12: 34-42.
  • 3Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands [J]. Drug Discov Today, 2004, 9: 641-651.
  • 4Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study [J]. JAMA, 2000, 284: 1247-1255.
  • 5Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial [J]. JAMA, 2000, 5, 283: 1695-1702.
  • 6Gore M, Carmichael J, Gordon A, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [J]. J Clin Oncol, 1997, 15: 2183-2193.
  • 7Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy [J]. Trends Mol Med, 2002, 8(4 Suppl): S14-18.
  • 8Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and an giogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor [J]. Clin Cancer Res, 2001, 7: 1459.
  • 9Terre C, Eclache V, Rousselot P. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia [J]. Leukemia, 2004, 18: 1340-1346.
  • 10LiHL WangCM.Analysis of mutations of bcr-abl gene and P53 gene in different phases of chronic myelogenous leukemia .兰州大学学报:自然科学版,2002,38:96-99.

共引文献13

同被引文献80

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部